RadarScope: ABBV — Analiza Fundamentala

Market Cap

$444.2B

P/E Ratio

123.3

Profit Margin

5.8%

ROE

68.0%

📈 Earnings Report — 2026-04

Ultimul trimestru raportat

EPS Actual

$2.65

▼ 2.2% QoQ▲ 7.7% YoY

EPS Estimat

$2.59

Beat by 2.3%

Revenue Actual

$15.00B

▼ 9.7% QoQ▲ 12.4% YoY

Revenue Estimat

$14.72B

Beat by 1.9%

Istoric Ultimele 4 Trimestre

2026-04

EPS Actual

$2.65

EPS Est.

$2.59

Revenue

$15.00B

Beat/Miss

Beat by 2.3%

2026-02

EPS Actual

$2.71

EPS Est.

$2.65

Revenue

$16.62B

Beat/Miss

Beat by 2.3%

2025-10

EPS Actual

$1.86

EPS Est.

$1.77

Revenue

$15.78B

Beat/Miss

Beat by 5.1%

2025-07

EPS Actual

$2.97

EPS Est.

$2.88

Revenue

$15.42B

Beat/Miss

Beat by 3.1%

Urmatorul Raport

Data

2026-07-31

EPS Estimat

$3.79

Revenue Estimat

$16.77B

💰 Dividende Recente

2026-07

$1.73

Yield: 271.42%

Plata: 2026-08

2026-04

$1.73

Yield: 323.39%

Plata: 2026-05

2026-01

$1.73

Yield: 310.24%

Plata: 2026-02

2025-10

$1.64

Yield: 289.98%

Plata: 2025-11

📊 Scoruri Companie

Crestere 7/10

Revenue & Profit Growth

Evaluare 4/10

P/E · P/B · P/S

Calitate 9/10

Marje · ROE · Datorii

Risc 3/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza indisponibila temporar.

💡 Vezi datele de mai jos

🐂 BULL CASE

Date financiare solide

Pozitie competitiva puternica

🐻 BEAR CASE

Evaluare ridicata

Incertitudine macro

TINE Analiza manuala recomandata

📊 Metrici Fundamentale

P/E TTM123.3

P/B TTM16.22

P/S TTM7.07

EV/EBITDA—

Gross Margin70.7%

Operating Margin27.6%

Net Margin5.8%

ROE68.0%

ROA2.7%

Debt/Equity—

Current Ratio0.80

FCF Yield4.7%

Dividend Yield2.7%

Beta0.31

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2025-12	$61.2B	$43.0B	$4.2B	$2.37
2024-12	$56.3B	$39.4B	$4.3B	$2.40
2023-12	$54.3B	$33.9B	$4.9B	$2.73
2022-12	$58.1B	$40.6B	$11.8B	$6.65

🏢 Profil Companie

CEORobert A. Michael

Angajati55000

IPO2013-01-02

Websitehttps://www.abbvie.com...

52W High$255.99

52W Low$184.39

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthriti...

🎯 Score Breakdown

Calitate Companie (Q) 9/10

Risc Speculativ (R) 3/10

Scor AI RadarScope 50/100

VERDICT FINAL

TINE

Analiza manuala recomandata

🔒 Analiza completa disponibila cu cont SignalRadar